{"disease":{"id":"spinocerebellar-disease","name":"Spinocerebellar disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"taltirelin","indication_name":"Spinocerebellar disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceredist","generic_name":"TALTIRELIN","company_name":"","drug_phase":"phase_2","molecular_target":"Thyrotropin-releasing hormone receptor","drug_class":"taltirelin","quality_score":0,"revenue":null,"mechanism":"Ceredist works by binding to the thyrotropin-releasing hormone receptor, which helps to regulate certain bodily functions."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04714307","title":"Neuropsychiatry and Cognition in SCA3/MJD","phase":"","overall_status":"UNKNOWN","enrollment_count":144,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false},{"nct_id":"NCT05822908","title":"A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Vico Therapeutics B. V.","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}